<i>α</i>-Synuclein Transgenic<i>Drosophila</i>As a Model of Parkinson's Disease and Related Synucleinopathies
-
- Hideya Mizuno
- School of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Hyogo 663-8179, Japan
-
- Nobuhiro Fujikake
- Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan
-
- Keiji Wada
- Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan
-
- Yoshitaka Nagai
- Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan
説明
<jats:p><jats:italic>α</jats:italic>-Synuclein (<jats:italic>α</jats:italic>-Syn) is a major component of protein inclusions known as Lewy bodies, which are hallmarks of synucleinopathies such as Parkinson's disease (PD). The<jats:italic>α</jats:italic>-Syn gene is one of the familial PD-causing genes and is also associated with an increased risk of sporadic PD. Numerous studies using<jats:italic>α</jats:italic>-Syn expressing transgenic animals have indicated that<jats:italic>α</jats:italic>-Syn plays a critical role in the common pathogenesis of synucleinopathies.<jats:italic>Drosophila melanogaster</jats:italic>has several advantages for modeling human neurodegenerative diseases and is widely used for studying their pathomechanisms and therapies. In fact,<jats:italic>Drosophila</jats:italic>models expressing<jats:italic>α</jats:italic>-Syn have already been established and proven to replicate several features of human PD. In this paper, we review the current research on synucleinopathies using<jats:italic>α</jats:italic>-Syn<jats:italic>Drosophila</jats:italic>models and, moreover, explore the possibilities of these models for comprehensive genetic analyses and large-scale drug screening towards elucidating the molecular pathogenesis and developing therapies for synucleinopathies.</jats:p>
収録刊行物
-
- Parkinson's Disease
-
Parkinson's Disease 2011 1-7, 2011
Wiley